Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$22.13 0.25 (1.14%) as of 4:30 Mon 6/10


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.87(B)
Last Volume: 1,475,978 Avg Vol: 2,431,686
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 17.5
Insider 6 Months    : 18.9
Insider 3/6 Months : 36.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 425,000 615,000 735,409 735,409
Total Buy Value $8,733,955 $12,666,689 $15,268,727 $15,268,727
Total People Bought 1 1 1 1
Total Buy Transactions 2 3 4 4
Total Shares Sold 88,818 224,987 601,659 1,021,249
Total Sell Value $1,938,121 $5,007,803 $12,908,109 $20,266,173
Total People Sold 5 7 9 12
Total Sell Transactions 6 10 17 28
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 985
  Page 7 of 40  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Wyszomierski Jack L Director   –       •      –    2022-04-04 4 OE $3.13 $125,200 D/D 40,000 279,888     -
   Haley Patrick J. EVP, Commercial   •       –      –    2022-04-01 4 AS $23.00 $230,000 D/D (10,000) 269,191 -16%     
   Haley Patrick J. EVP, Commercial   •       –      –    2022-04-01 4 OE $6.21 $62,100 D/D 10,000 279,191     -
   Haley Patrick J. EVP, Commercial   •       –      –    2022-03-31 4 AS $22.43 $224,300 D/D (10,000) 269,191 -14%     
   Haley Patrick J. EVP, Commercial   •       –      –    2022-03-31 4 OE $6.21 $62,100 D/D 10,000 279,191     -
   Hessekiel Jeffrey EVP, General Counsel & Sec   •       –      –    2022-03-29 4 AS $22.00 $292,226 D/D (13,283) 605,236 -2%     
   Hessekiel Jeffrey EVP, General Counsel & Sec   •       –      –    2022-03-28 4 AS $22.00 $103,774 D/D (4,717) 618,519 -1%     
   Haley Patrick J. EVP, Commercial   •       –      –    2022-03-04 4 A $0.00 $0 D/D 70,715 269,191     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2022-03-04 4 A $0.00 $0 D/D 59,490 402,485     -
   Hessekiel Jeffrey EVP, General Counsel & Sec   •       –      –    2022-03-04 4 A $0.00 $0 D/D 67,875 623,236     -
   Morrissey Michael M President and CEO   •       •      –    2022-03-04 4 A $0.00 $0 D/D 270,415 399,271     -
   Senner Christopher J. EVP and CFO   •       –      –    2022-03-04 4 A $0.00 $0 D/D 75,985 429,833     -
   Morrissey Michael M President and CEO   •       •      –    2022-03-02 4 GD $0.00 $0 I/I 50,000 1,196,316     -
   Garber Alan M Director   –       •      –    2022-03-01 4 AS $21.00 $447,321 D/D (21,301) 31,417 -1%     
   Garber Alan M Director   –       •      –    2022-03-01 4 OE $3.13 $125,200 D/D 40,000 52,718     -
   Haley Patrick J. EVP, Commercial   •       –      –    2022-02-25 4 S $19.53 $610,078 D/D (31,238) 198,476 -8%     
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2022-02-24 4 AS $20.00 $360,000 D/D (18,000) 555,361 7%     
   Feldbaum Carl B Director   –       •      –    2022-02-22 4 S $19.49 $389,800 D/D (20,000) 8,521 -10%     
   Feldbaum Carl B Director   –       •      –    2022-02-22 4 OE $3.13 $62,600 D/D 20,000 28,521     -
   Papadopoulos Stelios Director   –       •      –    2022-02-22 4 S $19.56 $1,653,113 D/D (84,515) 1,220,036 -10%     
   Hessekiel Jeffrey EVP and General Counsel   •       –      –    2022-02-15 4 D $18.59 $227,281 D/D (12,226) 573,361     -
   Morrissey Michael M President and CEO   •       •      –    2022-02-15 4 D $18.59 $1,211,083 D/D (65,147) 128,856     -
   Lamb Peter EVP, Scientific Strategy & CSO   •       –      –    2022-02-15 4 D $18.59 $375,090 D/D (20,177) 342,995     -
   Senner Christopher J. EVP and CFO   •       –      –    2022-02-15 4 D $18.59 $340,699 D/D (18,327) 353,848     -
   Haley Patrick J. EVP, Commercial   •       –      –    2022-02-15 4 D $18.59 $288,647 D/D (15,527) 229,714     -
  985 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 40
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us